The Effects of Artificial Lighting on Affective and Core Symptoms of Eating Disorder (METROPOLIS)

The Effects of Artificial Lighting on Affective and Core Symptoms of Eating Disorder - a Pilot Study

The primary objective of this pilot study is to explore the effect of artificial lighting on affective symptoms, and the secondary aim is to explore the effect of artificial lighting on core symptoms of eating disorders (ED).

Several lines of evidence, albeit from hypothesis generation studies, suggest that artificial lighting may have a positive effect on well-being, mental health and affective symptoms in ED. The rationale of this study is to investigate the effects of artificial lighting on affective symptoms and cores symptoms of ED in inpatients undergoing weight restoration/treatment for ED.

Study design: Single-blind, controlled, pilot intervention study with circadian light (CL) comparing two CL regimens effects on mood symptoms.

Planned number of subjects: 16 patients with a ICD-10 diagnosis of Anorexia Nervosa, that completes exposure to at least three weeks of the two different CL regimens (L1 and L2) in any order.

Study Overview

Status

Terminated

Intervention / Treatment

Detailed Description

The primary objective of this pilot study is to explore the effect of artificial lighting on affective symptoms, and the secondary aim is to explore the effect of artificial lighting on core symptoms of eating disorders (ED).

If an effect is indicated, the study will provide information on how to improve light exposure to ED patients in psychiatric treatment units. In addition, the outcomes may help identify a better system for measurement and adjustment of the specific light variables of colour temperature and light intensity.

Several lines of evidence, albeit from hypothesis generation studies, suggest that artificial lighting may have a positive effect on well-being, mental health and affective symptoms in ED. This is the rationale to investigate the effects of artificial lighting on affective symptoms and cores symptoms of ED in inpatients undergoing weight restoration/treatment for ED.

Study design: Single-blind, controlled, pilot intervention study with circadian light (CL) comparing two CL regimens effects on mood symptoms.

Planned number of subjects: 16 patients with a International Classification of Disorders 10 (ICD-10) diagnosis of Anorexia Nervosa, that completes exposure to at least three weeks of the two different CL regimens (L1 and L2) in any order.

Location: Mental Health Center Ballerup, department 14 (currently Department 5).

Diagnostic inventory: Eating Disorder Examination-Questionnaire (EDE-Q)

Study Type

Interventional

Enrollment (Actual)

22

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Capitol Region
      • Ballerup, Capitol Region, Denmark, 2750
        • Mental Health Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Primary diagnosis of Anorexia Nervosa (AN) or Bulimia Nervosa (BN) or Eating Disorder Not Otherwise specified (EDNOS)
  2. Age ≥18 and <65

Exclusion Criteria:

  1. Forced care
  2. Non-primary psychiatric disorder other than AN, BN, or EDNOS
  3. Binge Eating disorder
  4. Somatic unstable condition
  5. High suicidal behavior or risk

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: L1
regimen L1 has overall higher intensity, higher color temperature and less light fluctuations
Circadian lighting regimen with one major fluctuation, high light intensity and color
Active Comparator: L2
regimen L2 has lower intensity, lower color temperature and more light fluctuations.
Circadian lighting regimen with one major fluctuation, high light intensity and color

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
3 week change in total score of Major Depression Inventory
Time Frame: 3 weeks change from baseline
depression scoring, change in total score over three weeks. range 0-50. Higher values means more depressed. Mild depression: MDI total score from 21 to 25. Moderate depression: MDI total score from 26 to 30. Severe depression: MDI total score of 31 or higher.
3 weeks change from baseline
3 week change in total score of Eating Disorder Inventory 2
Time Frame: 3 weeks change from baseline
Eating disorder symptoms total score change over 3 weeks. range 0-273. Higher score means more Eating disorder symptoms.
3 weeks change from baseline
3 week change in video images based measure of Physical activity
Time Frame: 3 weeks change in physical activity from baseline
video images based measure of quantity of physical activity
3 weeks change in physical activity from baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
3 week change in BMI
Time Frame: 3 week change as a measure of weight change
change in Body Mass index
3 week change as a measure of weight change
3 week change in Visual analogue scale of mood
Time Frame: 3 weeks change from baseline
self assessed measure of mood symptoms, range 1-10. Higher score means more symptoms and feeling worse.
3 weeks change from baseline
3 week change in melatonin levels
Time Frame: 3 weeks change from baseline
urinary levels of melatonin
3 weeks change from baseline
3 week change in serotonin levels
Time Frame: 3 weeks change from baseline
Blood levels of serotonin
3 weeks change from baseline
3 week change in cortisol levels
Time Frame: 3 weeks change from baseline
Urinary levels of cortisol as a measure of stress
3 weeks change from baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2018

Primary Completion (Actual)

July 31, 2018

Study Completion (Actual)

August 31, 2018

Study Registration Dates

First Submitted

May 3, 2019

First Submitted That Met QC Criteria

May 10, 2019

First Posted (Actual)

May 13, 2019

Study Record Updates

Last Update Posted (Actual)

October 23, 2023

Last Update Submitted That Met QC Criteria

October 18, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • H-17022914

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All patient data

IPD Sharing Time Frame

within 12 months

IPD Sharing Access Criteria

open

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anorexia Nervosa

Clinical Trials on Circadian Lighting regimen

3
Subscribe